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Controllable Thioester-Based Hydrogen Sulfide Slow-releasing 
Donors as Cardioprotective Agents
Hong Yao,‡a Shanshan Luo,‡b Junkai Liu,a Shaowen Xie,a Yanpeng Liu,a Jinyi Xu,a Zheying Zhu,c and 
Shengtao Xua
Hydrogen sulfide (H2S) is an important signaling molecule with promising 
protective effects in many physiological and pathological processes. 
However, the study on H2S has been impeded by the lack of appropriate H2S 
donors that could mimic its slow-releasing process in vivo. Herein, we report 
the rational design, synthesis, and biological evaluation of a series of 
thioester-based H2S donors. These cysteine-activated H2S donors release 
H2S in a slow and controllable manner. Most of the donors comprising allyl 
moiety showed significant cytoprotective effects in H9c2 cellular models of 
oxidative damage. The most potent donor 5e decreased the mitochondrial 
membrane potential (MMP) loss and lactate dehydrogenase (LDH) release 
in H2O2-stimulated H9c2 cells. More importantly, donor 5e exhibited potent 
cardioprotective effect in an in vivo myocardial infarction (MI) mice model 
by reducing myocardial infarct size and cardiomyocytes apoptosis. Taken 
together, our studies demonstrated that these new allyl thioesters are 
potential cardioprotective agents by releasing H2S.
Introduction
H2S has been recognized as an important signaling molecule owing 
to its significant functions in many aspects of human health and 
disease.[1] Many studies have shown various therapeutic effects of 
H2S, including vasodilation, anti-inflammation, anti-oxidation, and 
cardiovascular protection.[2] In order to explore the physiological and 
pathological properties of H2S, researchers used inorganic sulfide 
salts such as Na2S and NaHS to mimic endogenous H2S generation.[3] 
However, the uncontrollable and rapid release of H2S from sulfide 
salts does not mimic the slow and controllable H2S production in the 
living system, which greatly limits their usage.[4] Considering these 
disadvantages, small H2S-releasing organic molecules (H2S donors) 
have been developed and used as the primary tools, mainly including 
diallyl trisulfide (DATS), derivative of Lawesson’s reagent (GYY4137), 
dithiolethione (ADT-OH), geminal-dithiol species (gem-dithiol) and 
so on (Figure 1).[5] More recently, donors based on esterase-
activation, pH-modulation, ROS-activation and cysteine-activation as 
well as their H2S-related biological effects have been reported.[6] 
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Figure 1. Representative H2S donors.
It should be noted that although a number of H2S donors have 
been reported, ideal donors with controllable and slow H2S-releasing 
properties are still lacking.[7] Recently, Liang and co-workers clarified 
the misunderstanding of diallyl disulfide (DADS) as a rapid H2S-
releasing donor, which was attributed to its DATS impurity.[8] The 
results showed that H2S was released in fact via a sluggish reaction 
of DADS with GSH through an α-carbon nucleophilic substitution 
pathway within hours. Thus, we envisioned the core structure of 
DADS (diallyl disulfide) to be valuable template for the design of H2S 
slow-releasing donors (Scheme 1, Step c). 
In addition, due to the ubiquitous targets of H2S, localized 
generation of H2S is highly desirable but remains a great challenge. 
Site-directed delivery of H2S by donors ideally shall be triggered by 
specific cellular species or events.[9] H2S has been found to improve 
cardiac functions and serve as a cardioprotectant for the treatment 
of heart failure and ischemic heart diseases.[10] Under the condition 
of cardiovascular injury, oxidative stress triggered by reactive oxygen 
species (ROS) including superoxide, hydroxyl radical and hydrogen 
peroxide plays a vital role.[11] As it is well known that the sulfide can 
be easily converted into disulfide under oxidative conditions, the 
oxidative stress in the injured cells could be slickly used to trigger the 
localized generation of H2S within injured cells (Scheme 1, Step b). [12] 
Based on the above researches, we envision that allyl mercaptan 
is a valuable template for the design of H2S slow-releasing donors 
with cardioprotective effect. However, the simplicity and instability 
of allyl mercaptan limit its direct application. Since 
transthioesterification is a common strategy to transfer thioester to 
thiol in the presence of Cys or GSH (Scheme 1, Step a).[13] We 
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designed a series of thioester-based hydrogen sulfide donors, which 
could release H2S in a controllable and slow manner.
Herein, we reported a class of thioester-based H2S donors with 
novel H2S-releasing mechanism and in vitro H2S-releasing kinetics. 
Also their protective effects on H9c2 cells subjected with H2O2 
challenge were evaluated, and the cardioprotective effects of 
selected donors in a mouse model of MI were presented.
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Scheme 1. Proposed controllable thioester-based hydrogen sulfide slow release donors.
Result and discussion
To test this idea, a series of thioester derivatives 5a-l were prepared 
and the synthesis route is illustrated in Scheme 2. Various readily 
available benzoic acids were used as the starting materials. The 
treatment of acids with thionyl chloride afforded acyl chlorides 2 as 
the reactive intermediates, which were further reacted with 
thioacetamide in toluene to give compounds 3 in almost quantitive 
yields. After hydrolysis, various thiobenzoic acids 4 were obtained, 
which were treated with alkyl bromides or benzyl bromides directly 
in the presence of triethylamine (TEA) to provide the desired 
compounds 5a-l in 72-88% total yields. We expected that different 
substituents would affect the reaction rates of compounds 5 with Cys 
to generate thiols, thereby regulating the rate of H2S generation.
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Scheme 2. Synthesis of thioester-based hydrogen sulfide donors 5a-l.
With these compounds in hand, we tested their H2S-releasing 
kinetics in aqueous buffers firstly. These thioesters were stable in 
PBS buffers, but a time- and dose-dependent H2S release was 
detected when Cys was added into the solutions using the standard 
methylene blue (MB) method.[14] Finally, the optimized condition 
was determined to be 100 µM donors in PBS buffer (pH 7.4, 50 mM) 
containing 10% THF in the presence of 10 equiv of Cys. As shown in 
Figure 2, taking compound 5a as the example, a maximum of 41.5 
µM of H2S at 8 h was detected from 100 µM donor in PBS buffer 
containing 1 mM Cys. To our surprise, other amino acid, like Gly or 
Lys, couldn’t trigger the H2S release of 5a, we supposed that it might 
be due to the weaker nucleophilicity of those amino acids. We then 
systematically compared the H2S-releasing capabilities of these 
donors, and the data are summarized in Table 1. In contrast to DATS 
(48.8%, 0.35 h), the results of our H2S donors showed that up to 52.2 
% of the H2S can be detected (compound 5f) and the release time 
lasts up to 8.5 h (compound 5k). All those thioester-based H2S donors 
could release H2S in a much slower manner than DATS.
S
O
PBS/THF(9:1), 37oC H2S
5a (100 M)
Figure 2. Cysteine mediated H2S release from compound 5a.
Table 1. H2S-releasing profiles of thioester-based hydrogen sulfide donors.
Donors Tpeak(h)
  [H2S]peak
(μM) Donors
Tpeak
(h)
[H2S]peak
(μM)
5a    8.0 41.5 5h 3.5 19.4
5b   7.0 17.5 5i 5.0 15.6
5c   6.5 38.3 5j 3.0 24.3
5d   5.0 34.5 5k 8.5 15.8
5e   8.0 50.6 5l 7.5 15.3
5f   6.0 52.2 DATS 0.27 48.8
5g   7.0 42.4
To better understand the mechanism of H2S generation from these 
thioester-based hydrogen sulfide donors, we analyzed the reaction 
between 5a and Cys (10 equiv). As shown in Scheme 3, the 
decomposition of 5a to 8 was monitored by the formation of 9 using 
mass spectrometric analysis (Supporting Information, Fig. S1). The 
formation of disulfide 10 from allyl mercaptan (8) was also confirmed 
by mass spectra and NMR (Fig. S2). Besides, a great decline in the 
release of H2S was observed under anaerobic conditions. On the 
basis of the products observed and the previous knowledge,[8] we 
proposed the following mechanism: The reaction is initiated by 
reversible thiol exchange between 5a and Cys to generate the allyl 
mercaptan (8), which suffers oxidation to form DADS (10). 
Meanwhile, the resultant S-benzoyl cysteine 7 should undergo a 
native chemical ligation (NCL)-type acyl transfer to form a more 
stable N-benzoyl cystein 9. Compound 10 then undergoes α-carbon 
nucleophilic substitution with Cys (Path A) or allyl mercaptan (Path 
R1 S
O
R2
Cys (10 equiv)
H2S
100 M PBS (pH 7.4, 50 mM)/THF(9:1), 37oC
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B) to generate perthiol intermediate (12), which releases H2S in the 
presence of Cys. However, it is worth mentioning that allyl sulfides 
are substantially active because of the presence of allylic system, the 
precise and comprehensive H2S-releaseing mechanism of these 
donors was not clear yet, additional pathways to generate the H2S 
might exist in this complex system.[15]
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Scheme 3. Proposed Mechanism of H2S generation.
H2S has been widely proposed to protect the cardiovascular 
system through its antioxidative role.[16] In order to test the 
protective effects of our newly synthesized H2S donors in cells, the 
H2S releasing abilities of these donors in cells were firstly verified in 
H9c2 cells by a selective H2S fluorescent probe WSP-1 (Fig. S3).[17] The 
results showed that the typical donor 5a released H2S well in H2O2-
stimulated H9c2 cells. Thus, in vitro model of cardiomyoblasts were 
established in H2O2-stimulated H9c2 cells. The cell viability was 
analyzed by MTT colorimetry and the results were exhibited in Table 
2. Compounds 5a, 5c-g significantly attenuated H2O2-induced cell 
damage at concentrations of both 20 and 50 µM. The weaker 
protective effects of these donors at higher concentrations (> 100 
μM) might be attributed to their poor solubility (data not shown). 
Overall, the protective effects of these donors were similar to that of 
NaHS, DADS and DATS, and were consistent with their H2S release 
abilities, suggesting that their protective effects are likely due to H2S 
release.
Table 2. Protective effect of compounds on H2O2-stimulated H9c2 cells.
Cell viability (%)
NO Comp.
1 μM 10 μM 20 μM 50 μM
1 5a 58.1 61.1 74.5 68.3
2 5b 59.6 64.2 66.3 66.9
3 5c 64.6 69.3 77.9 65.5
4 5d 62.8 65.8 68.9 71.1
5 5e 65.0 71.9 71.3 77.7
6 5f 66.0 65.7 64.4 70.5
7 5g 63.1 66.2 72.1 63.3
8 5h 62.8 66.0 69.9 61.7
9 5i 63.3 59.5 59.0 54.8
10 5j 63.7 55.4 57.1 55.2
11 5k 63.3 62.9 64.7 57.1
12 5l 62.6 59.6 57.1 53.8
13 NaHS 58.6 67.0 68.5 69.6
14 DATS 60.3 67.5 71.7 70.8
15 DADS 59.6 64.8 71.2 69.6
16 Model 51.9
aValues are expressed as means from three independent experiments, the bar graph 
expressed as mean ± SD was included in Supporting Information Fig. S4.
Cell viability is most often defined based on the integrity of the cell 
membrane. A common method for detecting cell viability is based on 
measuring the activity of cytoplasmic enzymes released by damaged 
cells, such as lactate dehydrogenase (LDH), which is a stable 
cytoplasmic enzyme found in all cells.[18] Thus, in this study, the 
contents of LDH in medium were measured to indicate the extent of 
cellular injury. As shown in Figure 3, the exposure of H9c2 cells to 
H2O2 (400 µM, 1 h) caused the damage of cell membrane, leading to 
the release of LDH to the medium. The LDH release was significantly 
reduced when cells were pretreated with different concentrations 
(10, 20, and 50 μM) of donors for 5 h in the presence of Cys (10 
equiv), indicating the protective effects of these compounds. Among 
these donors, 5e exhibited the most potent cardioprotective effect. 
Changes in the mitochondrial membrane potential (∆ψm, MMP) 
have been postulated to be early events in H2O2-induced apoptosis 
signaling pathway.[19] Thus, fluorescent probe JC-1 was used to 
measure the changes of ∆ψm of cells treated with 5e. As shown in 
Figure S5, normal H9c2 cells had bright red fluorescence, and cells 
treated with H2O2 appeared green fluorescence, indicating that H2O2 
caused severe damage to cells and reduced ∆ψm. The pre-incubation 
of cells with 20 or 50 μM of 5e greatly impeded this ∆ψm loss, as 
indicated by a decrease in green emission and an increase in red 
emission. These findings further confirmed that these H2S donors 
exhibited potent cellular protection against oxidative injury. 
Figure 3. LDH assay of compounds 5a-g on H9c2 cells. Cell viability was analyzed by LDH 
assay from culture media of indicated cells which were pretreated with different 
concentrations (10, 20, and 50 μM) of compounds for 5 h or NaHS (100 μM, 1 h). The 
data are expressed as percentages of H2O2-stimulated cells (model group). 
Figure 4. Isolated hearts from mice treated with different concentrations of 5e (15 
mg/kg/day, 30 mg/kg/day) were sliced into 2 mm sections and stained with TTC to 
determine the infarction size. (n=6 for each group). *p<0.05 versus model group, 
**p<0.01 versus model group. 
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The cardioprotective effects of 5e were further verified in vivo in 
the MI mice model.[20] Mice treated with 5e for 7 days were 
subjected to coronary occlusion and the hearts were harvested 72 h 
post MI. Infarct size was assessed with TTC staining (2,3,5-
triphenyltetrazolium chloride), this white compound was 
enzymatically reduced to red TPF (1,3,5-triphenylformazan) in living 
tissues, while it remains as white TTC in areas of infarction since 
these enzymes have been degraded due to apoptosis. For this reason, 
healthy viable heart muscle will be stained in deep red, while areas 
of potential infarctions will be more pale. Infarction size was 
calculated as the ratio of scar average circumferences to left 
ventricular average inner circumferences. The results showed that 
infarct size was significantly larger in post MI mice (Model group) 
than that in sham-operated mice (Normal group) (Figure 4a). 
Remarkably, donor 5e treatment relived myocardial infarction in a 
dose-dependent manner. Low (15 mg/kg/day) and high (30 
mg/kg/day) dose of 5e reduce infarction size to 74.75% and 63.97% 
of the model group, respectively (Figures 4b-c).
H&E staining was then applied to evaluate histological feature of 
infarcted hearts. As shown in Figure 5b, in peri-infarct heart, 
myofilaments condensed, leaving damaged gap junction with 
infiltrated nucleus from necrotic and apoptotic cells. However, donor 
5e significantly restrained the damage within epimyocardium and 
alleviated the morphological damage of cardiomyocytes (Figure 5c). 
Furthermore, TUNEL staining was used to determine apoptosis of 
cardiomyocytes in peri-infarction area. As shown in Figure S6, TUNEL 
positive staining cells were hardly found in Sham operated mice, 
while massive red fluorescent dots indicating fragments of DNA were 
found in heart section of model group. Donor 5e displayed an 
obvious benefit in reducing the number of TUNEL-positive cells.
Figure 5. H&E staining was performed using heart sections to determine the 
morphological changes. (a) Normal group; (b) Model group; (c) Treated with 5e, 30 
mg/kg/day. Scale bar: 10 μm.
In summary, a series of thioester-based H2S donors were 
developed. These donors are stable in aqueous solution, and release 
significant amounts of H2S in a slow and controllable manner in the 
presence of Cys. The most potent donor 5e exhibited promising 
cardioprotective activity against H2O2-induced oxidative stress by 
decreasing the mitochondrial membrane potential loss and lactate 
dehydrogenase release in H9c2 cells. More importantly, donor 5e 
also exhibited potent cardioprotective effects in an in vivo 
myocardial infarction mice model by reducing myocardial infarct size 
and cardiomyoblasts apoptosis. Taken together, our study 
demonstrated that the new allyl thioesters may have potential as 
cardioprotective agents by releasing H2S.                                                      
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